Finding 1179517 (2025-001)

Material Weakness Repeat Finding
Requirement
AB
Questioned Costs
-
Year
2025
Accepted
2026-03-14
Audit: 391892
Auditor: CBIZ CPAS PC

AI Summary

  • Core Issue: The entity overcharged indirect costs by $1,462 due to using an incorrect rate.
  • Impacted Requirements: Costs must be allowable and follow the approved indirect cost rate per 2 CFR 200.405 and grant agreements.
  • Recommended Follow-Up: Update grant management procedures and train staff on the correct indirect cost rates.

Finding Text

CRITERIA: Per 2 CFR 200.405 and the grant agreement, costs charged to federal awards must be allowable, allocable, and in accordance with the approved indirect cost rate agreement. CONDITION: The entity overcharged indirect costs to the federal award by $1,462 during the year ended September 30, 2025. CAUSE: The entity applied the incorrect indirect cost rate. EFFECT: Overcharging indirect costs reduces costs available for the program and hinders program administration. QUESTIONED COSTS: $1,462 CONTEXT: This error was found in AL #47.084 which was $81,720 of expenses included in the total of $6,097,828 of federal expenditures. Total indirect costs of $906,416 were tested during the period out of which $1,462 were misapplied. PRIOR YEAR FINDING: No RECOMMENDATION: We recommend the entity review and update its grant management procedures to ensure the correct indirect cost rate is applied to all federal awards and that staff are trained on the current rates in effect. VIEWS OF RESPONSIBLE OFFICIALS AND PLANNED CORRECTIVE ACTION: Please see management’s Corrective Action Plan included in this reporting package.

Corrective Action Plan

Planned Corrective Action: After review, it was determined that the wrong indirect rate was applied to a project. The overcharged amount was $1,461.69. The prime of this project was an industry sponsor and a CRADA was necessary for this work to be completed. It is the belief of the current OSRI management that the error accurred due to confusion that the funds came from an industry sponsor and not a federal agency. To correct this error, management will issue a payment of $1,461.69 to the sponsor. Planned Implementation Date of Corrective Action: Three inquiries were made by CBIZ on 1/5/26 regarding indirects charged by OSRI. On 1/6/26 OSRI management responded clearing up two of the three inquiries showing that the total indirects charged based on direct numbers were correct and that an adjustment had been made during the fiscal year in question to correct prior short falls. After a thorough review of the third inquiry, OSRI management on 1/8/26 reached out to the industry sponsor to inform them of our error and payment reimbursement was initiated. On 1/16/26 the industry sponsor confirmed receipt and cashed check for reimbursement.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1179489 2025-001
    Material Weakness Repeat
  • 1179490 2025-001
    Material Weakness Repeat
  • 1179491 2025-001
    Material Weakness Repeat
  • 1179492 2025-001
    Material Weakness Repeat
  • 1179493 2025-001
    Material Weakness Repeat
  • 1179494 2025-001
    Material Weakness Repeat
  • 1179495 2025-001
    Material Weakness Repeat
  • 1179496 2025-001
    Material Weakness Repeat
  • 1179497 2025-001
    Material Weakness Repeat
  • 1179498 2025-001
    Material Weakness Repeat
  • 1179499 2025-001
    Material Weakness Repeat
  • 1179500 2025-001
    Material Weakness Repeat
  • 1179501 2025-001
    Material Weakness Repeat
  • 1179502 2025-001
    Material Weakness Repeat
  • 1179503 2025-001
    Material Weakness Repeat
  • 1179504 2025-001
    Material Weakness Repeat
  • 1179505 2025-001
    Material Weakness Repeat
  • 1179506 2025-001
    Material Weakness Repeat
  • 1179507 2025-001
    Material Weakness Repeat
  • 1179508 2025-001
    Material Weakness Repeat
  • 1179509 2025-001
    Material Weakness Repeat
  • 1179510 2025-001
    Material Weakness Repeat
  • 1179511 2025-001
    Material Weakness Repeat
  • 1179512 2025-001
    Material Weakness Repeat
  • 1179513 2025-001
    Material Weakness Repeat
  • 1179514 2025-001
    Material Weakness Repeat
  • 1179515 2025-001
    Material Weakness Repeat
  • 1179516 2025-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.838 LUNG DISEASES RESEARCH $99,217
47.084 NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS $81,720
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $81,512
93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING $30,822
93.866 AGING RESEARCH $20,775
93.837 CARDIOVASCULAR DISEASES RESEARCH $19,705
93.395 CANCER TREATMENT RESEARCH $5,544
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $2,847
93.242 MENTAL HEALTH RESEARCH GRANTS $2,529